Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 16Neoplasm Metastasis 2Uveal Melanoma 1Skin Neoplasms 1Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 36Cyclophosphamide 24Nivolumab 23Ipilimumab 22aldesleukin 19Interleukin-2 15fludarabine 14Specimen Handling 12Dacarbazine 11fludarabine phosphate 10Magnetic Resonance Spectroscopy 10Temozolomide 9Radiosurgery 9Biopsy 9cemiplimab 8Paclitaxel 8dabrafenib 5binimetinib 5Vemurafenib 5Radiotherapy 5Carboplatin 5trametinib 4sargramostim 4encorafenib 4avelumab 4Pemetrexed 4Leucovorin 4Fluorouracil 4Cisplatin 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × peginterferon alfa-2b × Dermatologic × Clear all
NCT02218164 2022-10-07

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
8 enrolled 11 charts
Dermatologic

Carcinoma, Squamous Cell, Neoplasm Metastasis, Skin Neoplasms

NCT00221702 2010-10-13

EADO

University Hospital, Bordeaux

Phase 3 Completed
898 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡